Company intelligence / Profile preview

OHRO

Cambridge, MA, USA

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Ohro is a precision immunology company dedicated to transforming the treatment of inflammatory and autoimmune diseases. Founded by world-renowned scientists Nir Hacohen and Ramnik Xavier, the company leverages a high-resolution patient-mapping platform to identify the cellular and molecular drivers of disease directly from human clinical data. By integrating advanced computational biology with deep immunological insights, Ohro aims to develop targeted therapies for patients who do not respond to current standards of care. The company is led by CEO John Lepore, formerly of GSK, and is backed by prominent investors including GV. Ohro's approach focuses on defining disease endotypes to ensure the right medicine reaches the right patient.

Therapeutic areas: Immunology
Modalities: Small moleculeMonoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on OHRO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OHRO.

Explore the full profile